Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
K201 for Prevention of AF Recurrence Post-Cardioversion
NCT01067833Phase 2Terminated
- Sponsor
- Sequel Pharmaceuticals
- Start
- Apr 2010
- Primary completion
- Oct 2011
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of K201 in Atrial fibrillation (AFib) (4 arms), sponsored by Sequel Pharmaceuticals. Primary endpoints: time to first documented recurrence of symptomatic AF at 28 days, time to first documented recurrence of symptomatic or asymptomatic AF at 28 days and 4 more. Started Apr 2010; status: terminated.
02
Drugs
K201
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT01067833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01067833.